Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-κB and Btk

Joo Hyun Kim,1 Won Seog Kim1,2, Jung Yong Hong3, Kung Ju Ryu4, Seok Jin Kim1,2, Chaehwa Park1

1Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
2Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
3Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea
4Department of Health Science and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul 06351, Korea

Correspondence to: Won Seog Kim, email: wskimsmc@skku.edu
Chaehwa Park, email: cpark@skku.edu

Keywords: EBNA2, CCL3, CCL4, doxorubicin resistance, B cell lymphoma
Received: July 22, 2016 Accepted: December 01, 2016 Published: December 27, 2016

ABSTRACT

Epstein-Barr virus (EBV)-encoded nuclear antigen, EBNA2, expressed in EBV-infected B lymphocytes is critical for lymphoblastoid cell growth. Microarray profiling and cytokine array screening revealed that EBNA2 is associated with upregulation of the chemokines CCL3 and CCL4 in lymphoma cells. Depletion or inactivation of CCL3 or CCL4 sensitized DLBCL cells to doxorubicin. Our results indicate that EBV influences cell survival via an autocrine mechanism whereby EBNA2 increases CCL3 and CCL4, which in turn activate the Btk and NF-κB pathways, contributing to doxorubicin resistance of B lymphoma cells. Western blot data further confirmed that CCL3 and CCL4 direct activation of Btk and NF-κB. Based on these findings, we propose that a pathway involving EBNA2/Btk/NF-κB/CCL3/CCL4 plays a key role in doxorubicin resistance, and therefore, inhibition of specific components of this pathway may sensitize lymphoma cells to doxorubicin. Evaluation of the relationship between CCL3 expression and EBV infection revealed high CCL3 levels in EBV-positive patients. Our data collectively suggest that doxorubicin treatment for EBNA2-positive DLBCL cells may be effectively complemented with a NF-κB or Btk inhibitor. Moreover, evaluation of the CCL3 and CCL4 levels may be helpful for selecting DLBCL patients likely to benefit from doxorubicin treatment in combination with the velcade or ibrutinib.

INTRODUCTION

Epstein-Barr virus (EBV) preferentially infects B lymphocytes and transforms resting B cells into permanent, latently infected lymphoblastoid cell lines [1, 2, 3]. EBV comprises EBV nuclear antigen (EBNA 1, 2, 3A, 3B, 3C and –LP) and latent membrane (LMP 1, 2A and 2B) proteins. EBV-infected cells express a group of nuclear proteins that influence both viral and cellular transcription. Among these, EBNA2 plays an important role in B-cell transformation through transcriptional regulation of CD23 and the key viral genes, LMP1 and LMP2A [4, 5, 6].

Elevated levels of CCL3 and CCL4, also known as macrophage inflammatory protein-1α (MIP-1α) and -1β (MIP-1β) [7], have been detected in EBV-associated malignancies [8, 9, 10]. Both CCL3 and CCL4 are increased via BCR signaling and highlighted as biomarker genes in B cells [11, 12]. Moreover, elevated CCL3 and CCL4 plasma levels represent independent prognostic markers in chronic lymphocytic leukemia (CLL) patients [13]. CCL3 and CCL4 levels in patients with CLL are rapidly normalized after pharmacological inhibition of BCR signaling with idelalisib [14] or ibrutinib [15]. In diffuse large B cell lymphoma (DLBCL), CCL3 has been...
validated as one of the six most powerful independent predictors of survival [18]. CCL3 and CCL4 are associated with proliferation of B cells [19]. However, EBNA2 is yet to be explored as a therapeutic biomarker for drug treatment, despite evidence from earlier EBNA2 and BCR signaling-related studies.

In the present investigation, we addressed the functional consequences of EBNA2 expression in B cell lymphoma cell lines. Data from cDNA microarray and cytokine array analyses confirmed that EBNA2 increases CCL3 and CCL4 expression in DLBCL cells, in turn leading to increased survival signaling, including via the Btk and NF-κB pathways. Treatment with ibrutinib and velcade effectively prevented the upregulation of CCL3 and CCL4 induced by EBNA2, supporting the involvement of Btk and NF-κB signaling in cell survival. We further investigated the effects of doxorubicin alone and in combination with these inhibitors on DLBCL cells. The synergistic effects of the drug combinations further support the targeting of Btk or NF-κB as a promising strategy to enhance the therapeutic efficacy of drugs for EBV-positive DLBCL with high levels of circulating CCL3 or CCL4.

RESULTS

EBNA2 increases CCL3 and CCL4 expression in DLBCL cells

EBNA2 is a 497 residue-long nuclear protein that acts as a transcriptional activator. To identify the genes increased by EBNA2, we performed genome-wide analysis of gene transcripts using Illumina Human HT-12 v4 Expression BeadChip. Notably, the expression levels of 22 genes, including CCL3 (CCL3L3, CCL3, CCL3L1, CCL4L2, CCL4L1), were augmented more than two-fold in EBNA2-expressing cells, BJAB and U2932 (Supplementary Table 1, 2), as presented in Figure 1A. EBNA2 enhanced CCL3 and CCL4 mRNA expression in EBNA2-expressing B cells to a significant extent, compared to control cells. We confirmed EBNA2-mediated induction of CCL3 and CCL4 in two EBV-negative lymphoma cell lines, BJAB and U2932 (Figure 1B). Cytokine array data additionally revealed specific upregulation of CCL3 and CCL4 proteins by EBNA2 in BJAB cells (Figure 1C). To confirm the

---

**Figure 1: Induction of CCL3 and CCL4 expression by EBNA2.** A. Gene expression analysis of EBNA2-containing BJAB and U2932 cells, compared to empty vector control cells. B. BJAB, U2932, and primary cells were transiently transfected with EBNA2 or empty vector for 24 h. RT-PCR was performed to determine CCL3 and CCL4 mRNA levels according to EBNA2 expression. C. EBNA2-induced upregulation of CCL3 and CCL4. Cytokine expression in BJAB cells expressing EBNA2 or control vector. Individual cytokines were spotted in duplicate, and the identities of CCL3 and CCL4 indicated. Positive control spots are located at the corners of the human cytokine array. D. ELISA analysis of CCL3 and CCL4 protein levels in culture supernatants. Data represent mean values ± SEM of three independent experiments. Each experiment was performed with triplicate samples.
EBNA2-induced increase in CCL3 and CCL4 proteins, the cytokine levels in culture medium were evaluated using ELISA. As shown in Figure 1D, large amounts of CCL3 and CCL4 accumulated in the culture medium of EBNA2-expressing cell lines (BJAB, U2932, DG75, and Toledo) and primary B cell lymphoma cells.

Autocrine CCL3 and CCL4 play a critical role in EBNA2-induced survival of DLBCL cells

To determine the biological significance of our findings, we examined the effects of doxorubicin on survival of BJAB and U2932 cells overexpressing EBNA2. Within the BJAB cell group, the median inhibitory concentration (IC$_{50}$) of doxorubicin was 43 nM in EBNA2-expressing cells whereas that for empty vector-containing control cells was 16 nM ($P = 0.007$; Figure 2A). Similar results were obtained with the U2932 cell line. The data indicate that EBNA2-overexpressing cells are less sensitive to doxorubicin than non-expressing cells transfected with control vectors. In view of the finding that EBNA2 enhances the survival of doxorubicin-challenged cells, we further examined whether CCL3 and CCL4 depletion can sensitize cells to the drug. EBNA2-expressing BJAB cells were transduced with lentiviral vectors to silence CCL3 and CCL4, and gene expression verified via RT-PCR (Figure 2B). As shown in Figure 2B, CCL3 and CCL4 mRNA levels were significantly decreased in knockdown cells. Silencing of CCL3 and CCL4 caused a dramatic reduction in EBNA2-mediated survival of cells after doxorubicin treatment for 72 h (IC$_{50}$=55 nM and 62 nM, respectively), compared to control shRNA-transfected cells (IC$_{50}$=108 nM). Similar results were obtained in the experiment with CCL3 and CCL4-neutralizing antibodies. BJAB cells were incubated...
with neutralizing antibodies to inhibit CCL3 and CCL4, and depletion of individual cytokines verified using ELISA (Figure 2C). Treatment with CCL3 or CCL4-neutralizing antibodies sensitized EBNA2-expressing BJAB cells to doxorubicin (P < 0.03; Figure 2C). These findings suggest that expression of EBNA2 enhances the resistance of cancer cells to doxorubicin, which may be at least partially dependent on upregulation of CCL3 and CCL4.

**Activation of Btk and NF-κB induces CCL3 and CCL4, which re-enhance phosphorylation of Btk and NF-κB**

CCL3 and CCL4 are known biomarkers for B cell receptor pathway activation [11, 12]. To explore the potential signaling pathways involved in EBNA2 activity, we examined the phosphorylation of signaling proteins, including Btk, Akt, Mapk, NF-κB, and mTOR. As shown in Figure 3A, EBNA2 promoted the phosphorylation of NF-κB and Btk. To address the requirement for Btk and NF-κB in EBNA2-mediated induction of CCL3 and CCL4, Btk and NF-κB inhibitors were employed. We analyzed the promoter activity of NF-κB according to EBNA2 expression to determine whether EBNA2 increases NF-κB promoter activity. As shown in Figure 3B, NF-κB activity was enhanced by EBNA2. Inhibition of Btk (ibrutinib) and NF-κB (velcade) efficiently blocked EBNA2-induced upregulation of CCL3 and CCL4 transcripts (Figure 3C and 3D). In addition, CCL3 and CCL4 production were decreased in the presence of velcade and ibrutinib in EBNA2-expressing, but not EBNA2-negative control BJAB cells (Figure 3E and 3F). To examine whether CCL3 and CCL4 enhance p-Btk and p-NF-κB, we used recombinant human CCL3 and CCL4 proteins. Treatment of BJAB cells with CCL3 and CCL4 for 30 min and 1 h resulted in Btk and NF-κB phosphorylation, as shown in Figure 3G.

![Figure 3](image-url)
Inhibition of Btk or NF-κB sensitizes DLBCL cells to doxorubicin

Notably, co-administration of doxorubicin and ibrutinib induced a significant decrease in the viability of EBNA2-expressing cells, but not in control cells transfected with empty vector (Figure 4A). Similarly, growth inhibition was significantly enhanced upon combination with velcade in EBNA2-expressing cells, but not in control cells with empty vectors (Figure 4B). Moreover, combined treatment with doxorubicin and ibrutinib or velcade resulted in a highly synergistic reduction in cell viability with CI < 1.0. A Fraction-affected-Combination index (Fa-CI) plot was created using CompuSyn software. Consistently, co-treatment with doxorubicin and ibrutinib or velcade induced a marked decrease in sphere formation of EBNA2-expressing BJAB but not control cells transfected with empty vector (Figure 4C, 4D). Additionally, treatment of isolated primary cells from a DLBCL patient with a combination of doxorubicin and inhibitors (velcade or ibrutinib) was more efficacious, compared to doxorubicin or inhibitor alone (Figure 4E).

Among a total of 210 patients with DLBCL, 14 (6.7%) showed EBER positivity and 196 (93.3%) showed EBER negativity. We observed a trend of higher mean serum CCL3 in EBER-positive compared with EBER-negative patients, as shown in Table 1 and Figure 5 (2.02 pg/mL versus 7.20 pg/mL, P=0.073). The data signify a close association of EBNA2-induced CCL3 and CCL4 upregulation with Btk and NF-κB activation pathways, supporting the potential utility of Btk and/or NF-κB as promising targets to overcome chemoresistance of EBV-positive DLBCL.

DISCUSSION

Epstein-Barr virus nuclear antigen 2 (EBNA2) is essential for the capacity of the virus to transform B cells, and mainly characterized as a transcription factor. EBNA2 transcriptionally activate cellular genes, such as...
Table 1: Characteristics of the study samples (n = 210)

|                         | All patients (n=210) | EBER (-) (n=196) | EBER (+) (n=14) |
|-------------------------|----------------------|------------------|-----------------|
| **Age, no. (%)**        |                      |                  |                 |
| 60 y or less            | 123 (58.6)           | 119 (60.7)       | 4 (28.6)        |
| Older than 60 y         | 87 (41.4)            | 77 (39.3)        | 10 (71.4)       |
| **Sex, no. (%)**        |                      |                  |                 |
| Male                    | 128 (61.0)           | 122 (62.2)       | 6 (42.9)        |
| Female                  | 82 (39.0)            | 74 (37.8)        | 8 (57.1)        |
| **Performance status, no. (%)** |          |                  |                 |
| ECOG 0-1                | 173 (82.4)           | 162 (82.7)       | 11 (78.6)       |
| ECOG 2-4                | 37 (17.6)            | 34 (17.3)        | 3 (21.4)        |
| **Ann Arbor stage, no. (%)** |                  |                  |                 |
| Limited, I-II          | 103 (49.0)           | 97 (49.5)        | 6 (42.9)        |
| Advanced, III-IV       | 107 (51.0)           | 99 (50.5)        | 8 (57.1)        |
| **IPI risk group, no. (%)** |                  |                  |                 |
| Low/Low intermediate   | 130 (61.9)           | 124 (63.3)       | 6 (42.9)        |
| High intermediate/High | 80 (38.1)            | 72 (36.7)        | 8 (57.1)        |
| **Bone marrow involvement** |                |                  |                 |
| Negative               | 191 (91.0)           | 179 (91.3)       | 12 (85.7)       |
| Positive               | 19 (9.0)             | 17 (8.7)         | 2 (14.3)        |
| **Response to front-lineTx** |            |                  |                 |
| CR or PR               | 181 (86.2)           | 171 (87.2)       | 10 (71.4)       |
| SD or PD               | 29 (13.8)            | 25 (12.8)        | 4 (28.6)        |

ECOG; Eastern Cooperative Oncology Group, IPI; International Prognostic Index, CR; complete response, PR; partial response, SD; stable disease, PD; progressive disease.

Figure 5: Dot plots of serum CCL3 levels according to EBER status. Serum levels of CCL3 in all patients (n=210), those with EBER negativity (n=14, 6.7%), and those with EBER positivity (n=196, 93.3%).
as CD23, and the key viral genes, LMP1 and LMP2A. Moreover, EBNA2 has been shown to contribute to EBV-induced B-cell transformation by altering miR expression [20] and cellular morphology, and increase colony formation in soft agar and tumorigenicity in nude mice [21]. In the present study, we identified the molecular targets of EBNA2 and examined the effects of specific EBNA2 targets on the drug response of EBV-infected B lymphoma cells. CCL3 and CCL4, known biomarkers for BCR pathway activation and prognosis in DLBCL, were selected using gene expression analysis. Based on DAVID software, a total of 20 GO functions were enriched. Among these, increased were mainly enriched in 10 GO functions (Supplementary Table 3), the most significant being regulation of immune response. KEGG pathway enrichment analysis revealed that increased DEGs were mainly enriched in two pathways, specifically, the chemokine signaling pathway and cytokine receptor interactions (Supplementary Table 4).

CCL3 and CCL4 expression has been detected in various B cell-related tumors, including multiple myeloma and chronic lymphocytic leukemia (CLL) [11, 22]. CCL3 enhances migration and signaling pathways mediating survival and proliferation in multiple myeloma cells [22, 23]. Recently, the in vivo importance of CCL3 and CCL4 expression in DLBCL for B cell receptor pathway activation and prognostic serum markers was highlighted [11, 12]. Chronic lymphocytic leukemia (CLL) patients contain elevated plasma CCL3 and CCL4 levels [13]. Btk, a component of the BCR pathway, is considered a potential novel target for the treatment of B cell lymphoma, and the Btk inhibitor, ibrutinib, has been successfully applied in clinical trials. Moreover, elevated CCL3 and CCL4 levels have been shown to be normalized by the Btk inhibitor in patients with CLL [14, 15], indicating that the BCR signaling pathway is responsible for chemokine production.

The transcription factor, EBNA2, clearly contributes to EBV-induced B-cell transformation and tumorigenicity [20, 21]. However, the precise relationship between EBNA2 and chemoresistance remains poorly understood at present. We showed here that EBNA2 increases doxorubicin resistance through enhancing activation of Btk and NF-κB and upregulating CCL3 and CCL4. Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote EBV-triggered B cell proliferation [19]. In vivo, EBNA2 also functions as a transcription factor to promote LMP1 expression [5]. Upon ectopic expression of EBNA2 alone, cells showed elevated CCL3 and CCL4 expression and doxorubicin resistance in our experiments. We found that overexpression of EBNA2 and its targets, CCL3 and CCL4, led to doxorubicin resistance, independent of the pathway underlying LMP1-mediated protection of cancer cells against chemotherapeutic agents [24-28]. Interestingly, CCL3 and CCL4 enhanced phosphorylation of Btk and NF-κB in DLBCL cells in culture, suggesting that upregulation of these chemokines may be the underlying cause of doxorubicin resistance.

Experiments from the current study showed that CCL3 and CCL4 are increased and responsible for Btk and NF-κB activation, and ultimately, chemoresistance of EBNA2Expressing DLBCL cells. Knockdown of CCL3 or CCL4 sensitized EBNA2-expressing cells to doxorubicin, further supporting a role in chemoresistance. In addition, selective inhibition of Btk or NF-κB effectively enhanced doxorubicin sensitivity, accompanied by downregulation of CCL3 and CCL4. Earlier reports have reported an association of high-dose doxorubicin with fatal congestive heart failure [29]. Combination treatment with ibrutinib or velcade may thus help to lower the treatment dose of doxorubicin required. While Ponader and co-workers have reported that ibrutinib decreases secretion of CCL3 and CCL4 in CLL cells [15], the cancer cell-autonomous survival function of these chemokines is yet to be explored. EBNA2 has been shown to promote NF-κB signaling [5, 30], which may, in turn, transactivate EBNA2 expression [4]. Accordingly, we suggest that EBV-positive DLBCL cells require Btk or NF-κB signaling to maintain survival via EBNA2-mediated upregulation of CCL3 and CCL4. EBV-positive DLBCL is more common in Asian (8–11%) than Western populations (<5%). Asian patients with EBV-positive DLBCL have unique and unfavorable clinical features, including older age, more advanced stage and higher International Prognostic Index (IPI), compared to patients with EBV-negative DLBCL. Moreover, survival of patients with EBV-positive DLBCL is significantly worse than that of the EBV-negative DLBCL group [31-33]. Our data provide mechanistic insights into the clinical activities of inhibitors targeting Btk and/or NF-κB in combination with doxorubicin for treatment of EBV-positive DLBCL, and support the utility of circulating CCL3 or CCL4 as response predictors to combination treatments in DLBCL.

MATERIALS AND METHODS

Cell lines, culture conditions, transfection and inhibitors

The U2932 cell line was purchased from the Leibniz-Institut DSMZ-Deutsches Sammlung von Mikroorganismen und Zellkulturen GmbH (Braunschweig, Germany). BJAB cells and expression plasmids encoding wild-type EBNA2 were obtained from Dr. M. S. Kang (Sungkyunkwan University, Korea). DG75 and Toledo cells were obtained from Dr. S. J. Kim (Sungkyunkwan University, Korea). Cell lines were cultured in RPMI 1640 supplemented with heat-inactivated 10% fetal bovine serum (FBS), penicillin and streptomycin (Gibco-BRL, Grand Island, NY) in a 5% CO2-containing atmosphere. Primary human ABC DLBCL cells were obtained from pleural effusion of a patient with primary ABC DLBCL.
using a protocol that the Samsung Medical Center Institutional Review Board approved, in accordance with the Declaration of Helsinki. CCL3 and CCL4 shRNA were purchased from Sigma-Aldrich (Milwaukee, WI), and CCL3 and CCL4-neutralizing Ab and recombinant human proteins from R&D systems (Minneapolis, MN). Lymphoma cell lines were transiently transfected with the EBNA2-expressing plasmid pSG5 using the Amaxa electroporation system (Amaxa, Gaithersburg, MD). Primary ABC DLBCL cells were transfected using Amaxa program X-01 with T solution. Ibrutinib was acquired from Selleck Chemicals (Houston, TX77054).

**cDNA microarray analysis**

Genes expressed in EBNA2-containing and control BJAB and U2932 cells were analyzed on an Illumina HumanHT-12 v4.0 Expression BeadChip (Illumina, Inc., San Diego, CA). Target preparation and microarray processing procedures were performed as described in the Illumina Expression Beadchip Analysis Manual. The pre-processing procedure for cell intensity files (CEL) and subsequent microarray analyses were performed using Illumina GenomeStudio v2011.1 (Gene Expression Module v1.9.0). Data were subjected to global scale normalization. Differentially expressed genes were selected based on fold change and Student’s t-test data (over two-fold and P <0.01, respectively), compared with the corresponding controls.

**Reverse transcriptase-polymerase chain reaction**

Total RNA was prepared using a Qiagen RNA extraction kit (Qiagen, Valencia, CA), according to the manufacturer’s instructions. For reverse transcription, 2 μg RNA was treated with RNase-free DNase, and cDNA obtained using an Omniscript RT kit (Qiagen). The cDNA generated was amplified using primers specific for CCL3 and CCL4. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was amplified as the control. PCR products were visualized using 1.2% agarose gel electrophoresis in 1XTAE buffer containing SYBR Safe DNA Gel Stain (Invitrogen, Carlsbad, CA).

**Cytokine antibody array**

Supernatant fractions of EBNA2- or vector-transfected B cells were collected after 24 h transfection, and applied to RayBio human cytokine antibody array 7 (RayBiotech, Inc., Norcross, GA) according to the manufacturer’s instructions.

**ELISA**

CCL3 and CCL4 protein concentrations in the culture supernatants were determined using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Inc., Minneapolis, MN) in keeping with the manufacturer’s instructions.

**NF-kB promoter-luciferase reporter assay**

pGL3-NF-kB-Luc containing the luciferase gene under control of a NF-kB responsive element was obtained from Clontech (Mountain View, CA). The reporter construct and constitutively active Renilla reniformis luciferase-producing vector, pRL-TK (Promega, Madison, WI), were transfected into EBNA2-expressing BJAB cells via Amaxa electroporation. Firefly and Renilla luciferase activities were measured with the Dual-Luciferase Reporter Assay system, based on the manufacturer’s instructions (Promega, Madison, WI).

**Assessment of cell viability**

Drug effects on cell viability were monitored using trypan blue staining. Alternatively, the CCK-8 viability assay was performed. For the CCK-8 assay, cells were incubated in triplicate on a 96-well plate in the presence or absence of the indicated test samples within a final volume of 0.1 mL for 24 h at 37°C. Thereafter, 20 μL Cell Counting Kit-8 reagent (CCK-8; Dojindo Laboratories, Kumamoto, Japan) was added to each well. After 2 h incubation at 37°C, optical density (OD) at 450 nm was measured using a 96-well multisecan autocorer. Cell viability was expressed as a percentage: (OD of experimental sample/OD of control).

**Antibodies for western blot**

The antibodies employed for western blotting included those specific for p-p65(S536), p-Btk(S180), p-AKT(S473), AKT, p-CARD11(S652), p-p44/42 MAPK(T202/Y204), p44/42 MAPK, p-p70S6K(Thr389), p70S6K, (Cell Signaling, Beverly, MA) and EBNA2 (Millipore, Merrill JA).

**Sphere forming assay**

The sphere formation assay was performed by seeding cells (100 cells/96-well plate) in BMSC supernatant. Cells were incubated in triplicate in the presence or absence of the indicated test samples in a final volume of 0.1 mL at 37°C. On day 14, spheres on the plate were counted under phase-contrast microscopy.

**Measurement of CCL3 levels in patients**

The serum CCL3 concentration was measured in archived frozen samples of the Samsung Medical Center prospective cohort study (NCT#00822731). Archived serum sample aliquots stored at ~80°C were thawed for use in the cytokine assay. The CCL3 concentration was measured in serum using the Procarta cytokine profiling kit.
(Panomics, San Diego, CA, USA), and all measurements performed in duplicate.

EBER was detected using an EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA). We employed EBV-negative lymphoid tissues and the hybridization mixture without EBV oligonucleotides as the negative control. A positive reaction was defined as >20% cells showing nuclear positivity.

Statistical analyses

All experiments were repeated three times unless otherwise stated. Data presented in graphs represent mean ± standard error of means from three independent experiments performed in triplicate. Differences between two mean values were analyzed using t-test and graphs produced using GraphPad Prism 6.

ACKNOWLEDGMENTS

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI14C2223).

CONFLICTS OF INTEREST

The authors declare no competing financial interests.

REFERENCES

1. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004; 4:757-768.
2. Cohen JB, Kieff E. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol. 1991; 65:5880-5885.
3. Mannick JB, Cohen JB, Birkenbach M, Marchini A, Kieff E. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol. 1991; 65:6826-6837.
4. Portal D, Zhou H, Zhao B, Kharchenko PV, Lowry E, Wong L, Quackenbush J, Holloway D, Jiang S, Lu Y, Kieff E. Epstein-Barr virus nuclear antigen leader protein localizes to promoters and enhancers with cell transcription factors and EBNA2. Proc Natl Acad Sci U S A. 2013; 110:18537-18542.
5. Zhao B, Zou J, Wang H, Johanssen E, Peng CW, Quackenbush J, Mar JC, Morton CC, Friedman ML, Blacklow SC, Aster JC, Bernstein BE, Kieff E. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A. 2011; 108:14902-14907.
6. Hsieh JJ, Hayward SD. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2. Science. 1995; 28:560-563.
7. Eberlein J, Nguyen TT, Victorino F, Golden-Mason L, Rosen HR, Homann D. J Clin Invest. Comprehensive assessment of chemokine expression profiles by flow cytometry. 2010; 120:907-923.
8. Maggio EM, Van Den Berg A, Visser L, Diepstra A, Kluiver J, Emmens R, Poppema S. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer. 2002; 109:665-672.
9. Setsuda J, Teruya-Feldstein J, Harris NL, Ferry JA, Sorbara L, Gupta G, Jaffe ES, Tosato G. Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol. 1999; 155:257-265.
10. Miyauachi K, Urano E, Yoshiyama H, Komano J. Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma. Cancer Sci. 2011; 102:1236-1241.
11. Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nursetike cell cocultures and after BCR stimulation. Blood. 2009; 113:3050-3058.
12. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L et al. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic markers in diffuse large B cell lymphoma. Br J Haematol. 2015; 171:726-735.
13. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S et al. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011; 117:1662-1669.
14. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O'Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011; 118:3603-3612.
15. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012; 119:1182-1189.
16. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503-511.
17. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltane JM, Hurt EM, Zhao H, Averett L et al. The use of molecular profiling to predict survival
after chemotherapy for diffuse large-B-cell lymphoma. Lymphoma/Leukemia Molecular Profiling Project. N Engl J Med. 2002; 346:1937-1947.

18. Lossos IS, Czerwinski DK, Alizadeh AA, Wechsler MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004; 350:1828-1837.

19. Tsai SC, Lin SJ, Lin CJ, Chou YC, Lin JH, Yeh TH, Chen MR, Huang LM, Lu MY, Huang YC, Chen HY, Tsai CH. Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation. J Virol. 2013; 87:9041-9052.

20. Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, Severa M, Coccia EM, Bigi R, Cirone M, Ferretti E, Campese AF, Hummel M et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia. 2012; 26:2343-2352.

21. Shimakage M, Kurata A, Inoue H, Okamoto Y, Yutusudo M, Hakura A. Tumorigenicity of EBNA2-transfected cells. FEBS Lett. 1995; 371:245-248.

22. Lentzsch S, Gries M, Janz M, Bargou R, Dörken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood. 2003; 101:3568-3573.

23. Ma YR, Ma YH. MIP-1α enhances Jurkat cell transendothelial migration by up-regulating endothelial adhesion molecules VCAM-1 and ICAM-1. Leuk Res. 2014; 38:1327-1331.

24. Kim JH, Kim WS, Kang JH, Lim HY, Ko YH, Park C. Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1. FEBS Lett. 2007; 581:623-628.

25. Kim JH, Kim WS, Park C. SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death. Leuk Lymphoma. 2008; 49:1392-1398.

26. Kim JH, Kim WS, Yun Y, Park C. Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. Cell Signal. 2010; 22:1858-1863.

27. Kim JH, Kim WS, Park C. Epstein-Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. Leuk Lymphoma. 2012; 53:1586-1591.

28. Kim JH, Kim WS, Park C. PKD1 is critical for Epstein-Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab. Leuk Lymphoma. 2015; 56:194-201.

29. Barrett-Lee PJ, Dixon JM, Farrell C, Jones A, Leonard R, Murray N, Palmieri C, Plummer CJ, Stanley A, Verrill MW. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann. Oncol. 2009;20: 816-827.

30. Luftig M1, Prinarakis E, Yasui T, Tsichritzis T, Cahir-McFarland E, Inoue J, Nakano H, Mak TW, Yeh WC, Li X, Akira S, Suzuki N, Suzuki S, Mosialos G, Kieff E. Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci U S A. 2003;100:15595-15600.

31. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110:972-978.

32. Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ et al. EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol. 2015;26:548-555.

33. Hong JY, Ko YH, Kim SJ, Kim WS. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly: a concise review and update. Curr Opin Oncol. 2015;27:392-398.